Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
Holding VRNA?
Track your performance easily
VRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.39 - $43.73
Previous Close$41.66
Volume951.06K
Average Volume (3M)1.01M
Market Cap
$3.41B
Enterprise Value$3.20B
Total Cash (Recent Filing)$336.04M
Total Debt (Recent Filing)$122.31M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Feb 27, 2025EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding81,831,170
10 Day Avg. Volume889,233
30 Day Avg. Volume1,009,578
Standard Deviation0.25
R-Squared0.00962
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)25.20
Price to Sales (P/S)606.17
Price to Cash Flow (P/CF)-13.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue568.16
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-24.65
Forecast
1Y Price Target
$47.83Price Target Upside19.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Verona Pharma News
PremiumCompany Announcements
Verona Pharma Reports Strong Q3 Launch for COPD DrugBulls Say, Bears Say
Bulls Say
Market PositioningThe acceptance of a permanent J-code for Ohtuvayre is set to facilitate reimbursement and boost market uptake, supporting continued sales growth.
Regulatory MilestonesOhtuvayre received FDA approval, marking it as the first novel mechanism of action for COPD in over a decade, which enhances its market potential.
Sales GrowthOhtuvayre sales exceeded expectations, reflecting strong market demand and leading to an upward revision of the price target.
Bears Say
Commercial UptakeSlower-than-anticipated commercial uptake of ensifentrine in the U.S. due to greater-than-projected competitive pressures or other market challenges.
CompetitionCompetition in a market dominated by large pharma poses significant risks.
Trial DesignRisks include trial design which could impact the success of product development.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRNA FAQ
What was Verona Pharma Plc’s price range in the past 12 months?
Verona Pharma Plc lowest stock price was $11.39 and its highest was $43.73 in the past 12 months.
What is Verona Pharma Plc’s market cap?
Currently, no data Available
When is Verona Pharma Plc’s upcoming earnings report date?
Verona Pharma Plc’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Verona Pharma Plc’s earnings last quarter?
Verona Pharma Plc released its earnings results on Nov 04, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.002.
Is Verona Pharma Plc overvalued?
According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued.
Does Verona Pharma Plc pay dividends?
Verona Pharma Plc does not currently pay dividends.
What is Verona Pharma Plc’s EPS estimate?
Verona Pharma Plc’s EPS estimate is -$0.05.
How many shares outstanding does Verona Pharma Plc have?
Verona Pharma Plc has 81,831,170 shares outstanding.
What happened to Verona Pharma Plc’s price movement after its last earnings report?
Verona Pharma Plc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went up 9.062%.
Which hedge fund is a major shareholder of Verona Pharma Plc?
Among the largest hedge funds holding Verona Pharma Plc’s share is Perceptive Advisors LLC. It holds Verona Pharma Plc’s shares valued at 182M.
---
Verona Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.83 (19.40% Upside)
$47.83 (19.40% Upside)
Blogger Sentiment
Bullish
VRNA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $475.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.22%
12-Months-Change
Fundamentals
Return on Equity
-78.35%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Verona Pharma Plc
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
---
VRNA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive sentiment primarily due to the successful launch of Ohtuvayre, robust prescriber engagement, and the initiation of new clinical trials. Despite the increased expenses and significant net loss, the overall outlook remains positive with promising early sales and a solid financial position.Read More>---
VRNA Stock 12 Month Forecast
Average Price Target
$47.83
▲(19.40% Upside)
Technical Analysis
Best Analysts Covering VRNA
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+115.35%
assigned a buy rating 12 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +115.35% per trade.
---